Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diethylnorspermine

Drug Profile

Diethylnorspermine

Alternative Names: BENSPM; CI 1006; DE 333; DENSPM; N-N-diethylnorspermine

Latest Information Update: 20 Dec 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation
  • Developer Genzyme Corporation; Nippon Kayaku; University of Toronto
  • Class Antineoplastics; Polyamines; Small molecules
  • Mechanism of Action Adenosylmethionine decarboxylase inhibitors; Ornithine decarboxylase inhibitors; Spermidine-spermine N1-acetyltransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease; Cancer; Liver cancer; Psoriasis

Most Recent Events

  • 23 Aug 2007 Discontinued - Phase-I for Cancer in Japan (IV)
  • 28 Apr 2006 This compound is still in active development for Liver cancer
  • 30 Jul 2004 Phase-I/II clinical trials in Liver cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top